Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

by Alessio, N., Arena, F., Baldanti, F., Bergami, F., Cassaniti, I., Cavanna, L., Cicognini, D., Comolli, G., Ferrari, A., Lasagna, A., Lilleri, D., Lo Cascio, G., Pedrazzoli, P., Percivalle, E., Quaccini, M., Sammartino, J.C, Sarasini, A., Schiavo, R., Secondino, S.
Published 2022